Bevacizumab + Osimertinib Did Not Increase Progression-Free Survival versus Osimertinib Alone in Patients with Advanced Adenocarcinoma and EGFR T790M Mutations

2020 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

Study results show no increase in progression-free survival with combination treatment of osimertinib and bevacizumab compared with osimertinib alone for patients with advanced lung adenocarcinoma and an EGFR T790M mutation.

Several studies of first-generation EGFR tyrosine kinase inhibitors (TKIs) showed that dual treatment with an EGFR-TKI and an angiogenic inhibitor had potential as a treatment strategy for patients with EGFR-mutated lung adenocarcinoma. In particular, a preclinical study showed that a dual EGFR-TKI + angiogenic inhibitor treatment strategy presented promising results in an EGFR T790M–mutated model. Based on these initial studies, the authors sought to test the efficacy and safety of dual bevacizumab + osimertinib treatment in patients with EGFR T790M–mutated advanced lung adenocarcinoma. They presented the results during the ESMO Virtual Congress 2020.

Patients with advanced lung adenocarcinoma and an EGFR T790M mutation treated with a first- or second-generation EGFR-TKI were randomized 1:1 to receive osimertinib (80 mg daily; N = 41) or osimertinib + bevacizumab (15 mg/kg divided every 3 weeks; N = 81). The primary end point was progression-free survival (PFS); the secondary end points were overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), and safety. The authors hypothesized a 0.55 improvement in PFS in the osimertinib + bevacizumab cohort compared with osimertinib alone. To achieve this, ≥80 patients were needed to provide an 80% power and a 20% 2-sided significance.

The median age of patients was 68 years (range, 41-82 years), 41% were male, 7% had stage III cancer, 70% had stage IV cancer, 22% had a cancer recurrence, 46% had a performance status of 0, 54% had a performance status of 1, 26% had brain metastasis, and 21% had a history of cytotoxic chemotherapy.

The median PFS was 9.4 months for the osimertinib + bevacizumab arm compared with 13.5 months for osimertinib alone (hazard ratio [HR], 1.44; 95% confidence interval, 1.00-2.08; P = .20). The median TTF was 8.4 months for the osimertinib + bevacizumab arm compared with 11.2 months for osimertinib alone (HR, 1.54; P = .12). The osimertinib + bevacizumab arm did not reach a median OS, whereas the osimertinib-alone arm had a median OS of 22.1 months (P = .96). The ORR was 68% for the osimertinib + bevacizumab arm and 54% for the osimertinib-alone arm. The most common adverse events with a grade ≥3 rating for the osimertinib + bevacizumab arm were proteinuria (23%), hypertension (20%), and infection (10%).

The authors concluded that the dual treatment of osimertinib + bevacizumab for patients with advanced lung adenocarcinoma and an EGFR T790M mutation did not show increased PFS compared with osimertinib alone.

Reference
Toi Y, et al. ESMO 2020. Abstract 1259O.

Related Items
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in Case Reports, Lung Cancer
2022 Midyear Review: Non–Small-Cell Lung Cancer
JHOP - Supplements published on July 21, 2022 in Lung Cancer
First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in AACR Highlights, Lung Cancer
Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors
Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
The Effect of Various KRAS Mutations on NSCLC Susceptibility
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
Patterns of Biomarker Testing in Metastatic NSCLC in the Community Oncology Setting
2021 Year in Review - Non–Small-Cell Lung Cancer published on December 29, 2021 in Lung Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: